Abstract 239P
Background
With the induction of molecular targeted therapy and immune checkpoint inhibitors, treatment strategies for systemic treatment of metastatic clear cell renal cell carcinoma (mCCRCC) have been changed with improved survival. However, for those patients diagnosed as metastatic non-clear cell renal cell carcinoma (mNCRCC), systemic therapy designed and approved for mCCRCC have been used because no validated systemic therapy exists. This retrospective study aimed to identify prognostic factors for patients with mNCRCC treated with systemic therapy.
Methods
A total of 270 patients were reviewed. Among them, 41 patients who pathologically diagnosed as mNCRCC and received systemic therapy were retrospectively analyzed. Clinical and pathological data were retrieved and analyzed retrospectively. The progression free survival (PFS) and overall survival (OS) between mNCRCC and mCCRCC patients were compared. The OS for patients with mNCRCC was further investigated with univariate and multivariate Cox’s proportional hazards regression models.
Results
After a median follow-up of 31.3 months after first-line treatment initiation, the median PFS was 3.3 and 20.8 months for mNCRCC and mCCRCC, respectively (p<0.0001). The median OS was 19.6 and 54.4 months for mNCRCC and mCCRCC, respectively (p<0.0001). For patients with mNCRCC, univariate Cox proportional hazards model analyses revealed that the duration of first-line treatment (p<0.0001), the time to first-line treatment within 1 year (p=0.0201), high corrected serum calcium (p=0.0006), high neutrophil count (p=0.0003), and the baseline CRP level (p=0.0034) were significantly correlated with shorter OS, respectively. Furthermore, a multivariate analysis revealed the duration of first-line treatment (Hazard ratio (HR): 0.89, 95% CI: 0.81-0.97, p=0.007), the high corrected serum calcium (HR: 4.04, 95% CI: 1.58-10.37, p=0.004), and the baseline CRP level (HR: 1.15, 95% CI: 1.05-1.25, p=0.002) were independent predictors for OS in mNCRCC patients.
Conclusions
Patients with mNCCC resulted in shorter PFS and OS. Elevated baseline C-reactive protein, a prognostic factor for mCCRCC, was also correlated with shorter OS in mNCRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract